RGLS vs. XOMA, IRWD, VSTM, VNDA, SGMO, LXRX, ACHV, AGEN, DOMH, and FBIO
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Agenus (AGEN), Dominari (DOMH), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry.
Regulus Therapeutics vs.
Regulus Therapeutics (NASDAQ:RGLS) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
In the previous week, Regulus Therapeutics had 1 more articles in the media than XOMA. MarketBeat recorded 2 mentions for Regulus Therapeutics and 1 mentions for XOMA. XOMA's average media sentiment score of 1.63 beat Regulus Therapeutics' score of 0.66 indicating that XOMA is being referred to more favorably in the news media.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by company insiders. Comparatively, 7.2% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Regulus Therapeutics has higher earnings, but lower revenue than XOMA. XOMA is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Regulus Therapeutics received 51 more outperform votes than XOMA when rated by MarketBeat users. However, 65.82% of users gave XOMA an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote.
Regulus Therapeutics currently has a consensus target price of $10.80, suggesting a potential upside of 724.43%. XOMA has a consensus target price of $72.00, suggesting a potential upside of 206.12%. Given Regulus Therapeutics' higher possible upside, equities analysts plainly believe Regulus Therapeutics is more favorable than XOMA.
Regulus Therapeutics has a net margin of 0.00% compared to XOMA's net margin of -151.34%. XOMA's return on equity of -24.95% beat Regulus Therapeutics' return on equity.
Summary
Regulus Therapeutics beats XOMA on 9 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RGLS) was last updated on 2/22/2025 by MarketBeat.com Staff
